FORM N-PX PROXY VOTING RECORD
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | COLUMN 9 | COLUMN 10 | COLUMN 11 | COLUMN 12 | COLUMN 13 | COLUMN 14 | COLUMN 15 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NAME OF ISSUER |
CUSIP | ISIN | FIGI | MEETING DATE | VOTE DESCRIPTION | VOTE CATEGORY | DESCRIPTION OF OTHER CATEGORY | VOTE SOURCE | SHARES VOTED | SHARES ON LOAN | DETAILS OF VOTE | MANAGER NUMBER | SERIES ID | OTHER INFO | ||
| HOW VOTED | SHARES VOTED | FOR OR AGAINST MANAGEMENT | ||||||||||||||
| Acadia Healthcare Company, Inc. | 00404A109 | US00404A1097 | - | 05/23/2024 | Advisory vote on the compensation of the Company's named executive officers as presented in the Proxy Statement. | SECTION 14A SAY-ON-PAY VOTES |
- | - | 1177500.000000 | 0 | FOR |
1177500.000000 |
FOR |
- | - | |
| Accolade, Inc. | 00437E102 | US00437E1029 | - | 08/08/2023 | To approve, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the proxy statement in accordance with SEC rules. | SECTION 14A SAY-ON-PAY VOTES |
- | - | 2820000.000000 | 0 | FOR |
2820000.000000 |
FOR |
- | - | |
| AcelRx Pharmaceuticals, Inc. | 00444T209 | US00444T2096 | - | 10/10/2023 | To approve, on an advisory basis, the compensation of our named executive officers. | SECTION 14A SAY-ON-PAY VOTES |
- | - | 316460.000000 | 0 | FOR |
316460.000000 |
FOR |
- | - | |
| Aclaris Therapeutics, Inc. | 00461U105 | US00461U1051 | - | 06/06/2024 | To approve, on an advisory basis, the compensation of our named executive officers, as disclosed in the proxy statement accompanying this proxy card. | SECTION 14A SAY-ON-PAY VOTES |
- | - | 2753495.000000 | 0 | FOR |
2753495.000000 |
FOR |
- | - | |
| Adaptimmune Therapeutics Plc | 00653A107 | US00653A1079 | - | 05/14/2024 | To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers for the year ended December 31, 2023. | SECTION 14A SAY-ON-PAY VOTES |
- | - | 2425468.000000 | 0 | FOR |
2425468.000000 |
FOR |
- | - | |
| agilon health, inc. | 00857U107 | US00857U1079 | - | 05/29/2024 | To approve, by advisory vote, the compensation paid to the Company's named executive officers. | SECTION 14A SAY-ON-PAY VOTES |
- | - | 7347792.000000 | 0 | FOR |
7347792.000000 |
FOR |
- | - | |
| Agios Pharmaceuticals, Inc. | 00847X104 | US00847X1046 | - | 06/20/2024 | To vote, on an advisory basis, to approve the compensation paid to our named executive officers. | SECTION 14A SAY-ON-PAY VOTES |
- | - | 1294687.000000 | 0 | FOR |
1294687.000000 |
FOR |
- | - | |
| Akero Therapeutics, Inc. | 00973Y108 | US00973Y1082 | - | 06/07/2024 | To consider and act upon a non-binding, advisory vote to approve the compensation of our named executive officers. | SECTION 14A SAY-ON-PAY VOTES |
- | - | 1299888.000000 | 0 | FOR |
1299888.000000 |
FOR |
- | - | |
| Align Technology, Inc. | 016255101 | US0162551016 | - | 05/22/2024 | ADVISORY VOTE ON NAMED EXECUTIVES' COMPENSATION Consider an Advisory Vote to Approve the Compensation of our Named Executive Officers. | SECTION 14A SAY-ON-PAY VOTES |
- | - | 220000.000000 | 0 | FOR |
220000.000000 |
FOR |
- | - | |
| Alnylam Pharmaceuticals, Inc. | 02043Q107 | US02043Q1076 | - | 05/16/2024 | To approve, in a non-binding advisory vote, the compensation of Alnylam's named executive officers. | SECTION 14A SAY-ON-PAY VOTES |
- | - | 227400.000000 | 0 | FOR |
227400.000000 |
FOR |
- | - | |
| Altimmune, Inc. | 02155H200 | US02155H2004 | - | 09/28/2023 | Hold an advisory vote on the compensation of the Company's named executive officers as disclosed in the attached Proxy Statement. | SECTION 14A SAY-ON-PAY VOTES |
- | - | 156992.000000 | 0 | FOR |
156992.000000 |
FOR |
- | - | |
| Altimmune, Inc. | 02155H200 | US02155H2004 | - | 09/28/2023 | Hold an advisory vote on the frequency of the advisory vote on the compensation of the Company's named executive officers as disclosed in the attached Proxy Statement. | SECTION 14A SAY-ON-PAY VOTES |
- | - | 156992.000000 | 0 | ONE YEAR |
156992.000000 |
FOR |
- | - | |
| Amicus Therapeutics, Inc. | 03152W109 | US03152W1099 | - | 06/06/2024 | Approval, on an advisory basis, the Company's executive compensation. | SECTION 14A SAY-ON-PAY VOTES |
- | - | 1152656.000000 | 0 | FOR |
1152656.000000 |
FOR |
- | - | |
| Amylyx Pharmaceuticals, Inc. | 03237H101 | US03237H1014 | - | 06/06/2024 | To approve, on a non-binding, advisory basis, the compensation of our named executives officers. | SECTION 14A SAY-ON-PAY VOTES |
- | - | 1011412.000000 | 0 | FOR |
1011412.000000 |
FOR |
- | - | |
| Amylyx Pharmaceuticals, Inc. | 03237H101 | US03237H1014 | - | 06/06/2024 | To vote, on a non-binding, advisory basis, on the preferred frequency of future advisory votes on the compensation of our named executives officers. | SECTION 14A SAY-ON-PAY VOTES |
- | - | 1011412.000000 | 0 | ONE YEAR |
1011412.000000 |
FOR |
- | - | |
| Aurinia Pharmaceuticals Inc. | 05156V102 | CA05156V1022 | - | 06/14/2024 | Advisory Resolution on Executive Compensation To approve, on a non-binding advisory basis, a "say on pay" resolution regarding the Company's executive compensation set forth in the Company's Proxy Statement/Circular. | SECTION 14A SAY-ON-PAY VOTES |
- | - | 975975.000000 | 0 | FOR |
975975.000000 |
FOR |
- | - | |
| Azenta, Inc. | 114340102 | US1143401024 | - | 01/30/2024 | To approve by a non-binding advisory vote the compensation of the Company's named executive officers. | SECTION 14A SAY-ON-PAY VOTES |
- | - | 28272.000000 | 0 | FOR |
28272.000000 |
FOR |
- | - | |
| Azenta, Inc. | 114340102 | US1143401024 | - | 01/30/2024 | To recommend, on an advisory basis, the frequency of holding an advisory vote on executive compensation. | SECTION 14A SAY-ON-PAY VOTES |
- | - | 28272.000000 | 0 | ONE YEAR |
28272.000000 |
FOR |
- | - | |
| Beam Therapeutics Inc. | 07373V105 | US07373V1052 | - | 06/05/2024 | Approve, on an advisory basis, the compensation of our named executive officers. | SECTION 14A SAY-ON-PAY VOTES |
- | - | 30.000000 | 0 | FOR |
30.000000 |
FOR |
- | - | |
| BioCryst Pharmaceuticals, Inc. | 09058V103 | US09058V1035 | - | 06/12/2024 | To approve, on an advisory basis, the Company's executive compensation. | SECTION 14A SAY-ON-PAY VOTES |
- | - | 3530680.000000 | 0 | FOR |
3530680.000000 |
FOR |
- | - | |
| Biohaven Ltd. | G1110E107 | VGG1110E1079 | - | 04/30/2024 | A non-binding advisory vote on the frequency of future advisory votes on the Company's named executive officer compensation. | SECTION 14A SAY-ON-PAY VOTES |
- | - | 63349.000000 | 0 | ONE YEAR |
63349.000000 |
FOR |
- | - | |
| Blueprint Medicines Corporation | 09627Y109 | US09627Y1091 | - | 06/12/2024 | Approval of a non-binding advisory vote on the frequency of future advisory votes on the compensation paid to our named executive officers. | SECTION 14A SAY-ON-PAY VOTES |
- | - | 2498449.000000 | 0 | ONE YEAR |
2498449.000000 |
FOR |
- | - | |
| Blueprint Medicines Corporation | 09627Y109 | US09627Y1091 | - | 06/12/2024 | Approval of a non-binding advisory vote on the compensation paid to our named executive officers. | SECTION 14A SAY-ON-PAY VOTES |
- | - | 2498449.000000 | 0 | FOR |
2498449.000000 |
FOR |
- | - | |
| Boston Scientific Corporation | 101137107 | US1011371077 | - | 05/02/2024 | To approve, on a non-binding, advisory basis, the compensation of our named executive officers. | SECTION 14A SAY-ON-PAY VOTES |
- | - | 1204561.000000 | 0 | FOR |
1204561.000000 |
FOR |
- | - | |
| Celldex Therapeutics, Inc. | 15117B202 | US15117B2025 | - | 06/13/2024 | To approve, on an advisory basis, the compensation of the Company's Named Executive Officers as disclosed in this Proxy Statement. | SECTION 14A SAY-ON-PAY VOTES |
- | - | 1372185.000000 | 0 | FOR |
1372185.000000 |
FOR |
- | - | |
| Cerevel Therapeutics Holdings, Inc. | 15678U128 | US15678U1280 | - | 02/16/2024 | To approve, on a non-binding, advisory basis, certain compensation that will or may be paid or become payable to Cerevel's named executive officers that is based on or otherwise relates to the Merger; and | SECTION 14A SAY-ON-PAY VOTES |
- | - | 2674245.000000 | 0 | FOR |
2674245.000000 |
FOR |
- | - | |
| Charles River Laboratories International, Inc. | 159864107 | US1598641074 | - | 05/08/2024 | Advisory Approval of 2023 Executive Officer Compensation | SECTION 14A SAY-ON-PAY VOTES |
- | - | 34.000000 | 0 | FOR |
34.000000 |
FOR |
- | - | |
| Chinook Therapeutics, Inc. | 16961L106 | US16961L1061 | - | 08/02/2023 | To consider and vote upon the proposal to approve, on an advisory (non-binding) basis, certain compensation that may be paid or become payable to Chinook's named executive officers in connection with the Merger. | SECTION 14A SAY-ON-PAY VOTES |
- | - | 396280.000000 | 0 | AGAINST |
396280.000000 |
AGAINST |
- | - | |
| Collegium Pharmaceutical, Inc. | 19459J104 | US19459J1043 | - | 05/16/2024 | Approval of, on an advisory basis, the compensation of the Company's named executive officers. | SECTION 14A SAY-ON-PAY VOTES |
- | - | 412043.000000 | 0 | FOR |
412043.000000 |
FOR |
- | - | |
| DexCom, Inc. | 252131107 | US2521311074 | - | 05/22/2024 | To provide a non-binding advisory vote on the compensation of our named executive officers for the fiscal year ended December 31, 2023. | SECTION 14A SAY-ON-PAY VOTES |
- | - | 398410.000000 | 0 | FOR |
398410.000000 |
FOR |
- | - | |
| Dynavax Technologies Corporation | 268158201 | US2681582019 | - | 05/23/2024 | To approve, on an advisory basis, the compensation of our named executive officers, as disclosed in the proxy statement accompanying this Notice. | SECTION 14A SAY-ON-PAY VOTES |
- | - | 1628856.000000 | 0 | FOR |
1628856.000000 |
FOR |
- | - | |
| Edwards Lifesciences Corporation | 28176E108 | US28176E1082 | - | 05/07/2024 | Advisory Vote to Approve Named Executive Officer Compensation | SECTION 14A SAY-ON-PAY VOTES |
- | - | 647300.000000 | 0 | FOR |
647300.000000 |
FOR |
- | - | |
| Eli Lilly and Company | 532457108 | US5324571083 | - | 05/06/2024 | Approval, on an advisory basis, of the compensation paid to the company's named executive officers. | SECTION 14A SAY-ON-PAY VOTES |
- | - | 94000.000000 | 0 | FOR |
94000.000000 |
FOR |
- | - | |
| ESSA Pharma Inc. | 29668H708 | CA29668H7085 | - | 03/06/2024 | Advisory Vote on Executive Compensation The approval, on a non-binding, advisory basis, of the compensation paid to the Company's named executive officers. | SECTION 14A SAY-ON-PAY VOTES |
- | - | 553322.000000 | 0 | FOR |
553322.000000 |
FOR |
- | - | |
| Evolent Health, Inc. | 30050B101 | US30050B1017 | - | 06/06/2024 | Proposal to approve the compensation of our named executive officers for 2023 on an advisory basis. | SECTION 14A SAY-ON-PAY VOTES |
- | - | 3985091.000000 | 0 | FOR |
3985091.000000 |
FOR |
- | - | |
| Evolent Health, Inc. | 30050B101 | US30050B1017 | - | 06/06/2024 | Proposal to approve the selection of the frequency of future advisory votes on executive compensation on an advisory basis. | SECTION 14A SAY-ON-PAY VOTES |
- | - | 3985091.000000 | 0 | ONE YEAR |
3985091.000000 |
FOR |
- | - | |
| Exact Sciences Corporation | 30063P105 | US30063P1057 | - | 06/13/2024 | To approve, on an advisory basis, the compensation of our named executive officers. | SECTION 14A SAY-ON-PAY VOTES |
- | - | 921559.000000 | 0 | FOR |
921559.000000 |
FOR |
- | - | |
| Freshpet, Inc. | 358039105 | US3580391056 | - | 10/10/2023 | Non-binding advisory vote to approve the compensation of the Company's named executive officers. | SECTION 14A SAY-ON-PAY VOTES |
- | - | 662137.000000 | 0 | FOR |
662137.000000 |
FOR |
- | - | |
| Gossamer Bio, Inc. | 38341P102 | US38341P1021 | - | 06/06/2024 | Approval, on an advisory basis, of the compensation of the Company's named executive officers as disclosed in the proxy statement. | SECTION 14A SAY-ON-PAY VOTES |
- | - | 2978546.000000 | 0 | AGAINST |
2978546.000000 |
AGAINST |
- | - | |
| Horizon Therapeutics Public Limited Company | G46188101 | IE00BQPVQZ61 | - | 07/27/2023 | Approval, on an advisory basis, of the compensation of our named executive officers, as disclosed in this Proxy Statement. | SECTION 14A SAY-ON-PAY VOTES |
- | - | 674321.000000 | 0 | AGAINST |
674321.000000 |
AGAINST |
- | - | |
| Humana Inc. | 444859102 | US4448591028 | - | 04/18/2024 | Non-binding advisory vote for the approval of the compensation of the named executive officers as disclosed in the 2024 proxy statement. | SECTION 14A SAY-ON-PAY VOTES |
- | - | 147408.000000 | 0 | FOR |
147408.000000 |
FOR |
- | - | |
| IDEXX Laboratories, Inc. | 45168D104 | US45168D1046 | - | 05/06/2024 | Advisory Vote on Executive Compensation. To approve a nonbinding advisory resolution on the Company's executive compensation (Proposal Three). | SECTION 14A SAY-ON-PAY VOTES |
- | - | 179250.000000 | 0 | FOR |
179250.000000 |
FOR |
- | - | |
| Immunocore Holdings Plc | 45258D105 | US45258D1054 | - | 05/23/2024 | To approve, on advisory basis, the compensation of the Company's named executive officers, as disclosed in the proxy statement. | SECTION 14A SAY-ON-PAY VOTES |
- | - | 2407895.000000 | 0 | FOR |
2407895.000000 |
FOR |
- | - | |
| Immunocore Holdings Plc | 45258D105 | US45258D1054 | - | 05/23/2024 | To indicate, on an advisory basis, the preferred frequency of shareholder advisory votes on the compensation of the Company's named executive officers. | SECTION 14A SAY-ON-PAY VOTES |
- | - | 2407895.000000 | 0 | ONE YEAR |
2407895.000000 |
FOR |
- | - | |
| ImmunoGen, Inc. | 45253H101 | US45253H1014 | - | 01/31/2024 | A proposal to approve, on a non-binding, advisory basis, the compensation that may be paid or become payable to ImmunoGen's named executive officers that is based on or otherwise relates to the Merger Agreement and the transactions contemplated by the Merger Agreement; and | SECTION 14A SAY-ON-PAY VOTES |
- | - | 759365.000000 | 0 | AGAINST |
759365.000000 |
AGAINST |
- | - | |
| Inspire Medical Systems, Inc. | 457730109 | US4577301090 | - | 05/02/2024 | Approval, on an advisory (non-binding) basis, of the compensation of the Company's named executive officers. | SECTION 14A SAY-ON-PAY VOTES |
- | - | 130000.000000 | 0 | FOR |
130000.000000 |
FOR |
- | - | |
| Insulet Corporation | 45784P101 | US45784P1012 | - | 05/22/2024 | To approve, on a non-binding, advisory basis, the compensation of certain executive officers. | SECTION 14A SAY-ON-PAY VOTES |
- | - | 320000.000000 | 0 | FOR |
320000.000000 |
FOR |
- | - | |
| Intuitive Surgical, Inc. | 46120E602 | US46120E6023 | - | 04/25/2024 | To approve, by advisory vote, the compensation of the Company's Named Executive Officers. | SECTION 14A SAY-ON-PAY VOTES |
- | - | 275930.000000 | 0 | FOR |
275930.000000 |
FOR |
- | - | |
| iRhythm Technologies, Inc. | 450056106 | US4500561067 | - | 05/29/2024 | To approve, on a non-binding advisory basis, the named executive officer compensation. | SECTION 14A SAY-ON-PAY VOTES |
- | - | 392250.000000 | 0 | AGAINST |
392250.000000 |
AGAINST |
- | - | |
| iRhythm Technologies, Inc. | 450056106 | US4500561067 | - | 05/29/2024 | To select, on a non-binding advisory basis, whether future advisory votes on the compensation of our named executive officers should be every one, two, or three years. | SECTION 14A SAY-ON-PAY VOTES |
- | - | 392250.000000 | 0 | ONE YEAR |
392250.000000 |
FOR |
- | - | |
| Karuna Therapeutics, Inc. | 48576A100 | US48576A1007 | - | 03/12/2024 | To approve, on an advisory, non-binding basis, certain compensation that will or may be paid by Karuna to its named executive officers that is based on or otherwise relates to the merger of Merger Sub with and into Karuna pursuant to the merger agreement. | SECTION 14A SAY-ON-PAY VOTES |
- | - | 514392.000000 | 0 | FOR |
514392.000000 |
FOR |
- | - | |
| Krystal Biotech, Inc. | 501147102 | US5011471027 | - | 05/17/2024 | Approval of the compensation of the Company's named executive officers, on a non-binding, advisory basis. | SECTION 14A SAY-ON-PAY VOTES |
- | - | 100773.000000 | 0 | FOR |
100773.000000 |
FOR |
- | - | |
| Kymera Therapeutics, Inc. | 501575104 | US5015751044 | - | 06/18/2024 | To approve, on a non-binding advisory basis, the compensation of our named executive officers; | SECTION 14A SAY-ON-PAY VOTES |
- | - | 1505750.000000 | 0 | FOR |
1505750.000000 |
FOR |
- | - | |
| LifeStance Health Group, Inc. | 53228F101 | US53228F1012 | - | 06/03/2024 | Approval, on an advisory basis, of the compensation of the Company's named executive officers; | SECTION 14A SAY-ON-PAY VOTES |
- | - | 4767125.000000 | 0 | AGAINST |
4767125.000000 |
AGAINST |
- | - | |
| LifeStance Health Group, Inc. | 53228F101 | US53228F1012 | - | 06/03/2024 | Approval, on an advisory basis, of the frequency of future advisory votes on the compensation paid to the Company's named executive officers; and | SECTION 14A SAY-ON-PAY VOTES |
- | - | 4767125.000000 | 0 | ONE YEAR |
4767125.000000 |
FOR |
- | - | |
| MacroGenics, Inc. | 556099109 | US5560991094 | - | 05/21/2024 | To approve, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the proxy materials. | SECTION 14A SAY-ON-PAY VOTES |
- | - | 1305250.000000 | 0 | FOR |
1305250.000000 |
FOR |
- | - | |
| Madrigal Pharmaceuticals, Inc. | 558868105 | US5588681057 | - | 06/25/2024 | Advisory vote to approve executive compensation. | SECTION 14A SAY-ON-PAY VOTES |
- | - | 285931.000000 | 0 | FOR |
285931.000000 |
FOR |
- | - | |
| Mersana Therapeutics, Inc. | 59045L106 | US59045L1061 | - | 06/11/2024 | To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers. | SECTION 14A SAY-ON-PAY VOTES |
- | - | 3046782.000000 | 0 | FOR |
3046782.000000 |
FOR |
- | - | |
| Merus N.V. | N5749R100 | NL0011606264 | - | 05/07/2024 | Approval, on an advisory (non-binding) basis, of the compensation of Merus N.V.'s named executive officers. | SECTION 14A SAY-ON-PAY VOTES |
- | - | 1147134.000000 | 0 | FOR |
1147134.000000 |
FOR |
- | - | |
| Mirati Therapeutics, Inc. | 60468T105 | US60468T1051 | - | 12/13/2023 | To approve, by non-binding, advisory vote, compensation that may be paid or become payable by Mirati to its named executive officers in connection with the Merger. | SECTION 14A SAY-ON-PAY VOTES |
- | - | 835776.000000 | 0 | AGAINST |
835776.000000 |
AGAINST |
- | - | |
| Mirum Pharmaceuticals, Inc. | 604749101 | US6047491013 | - | 06/05/2024 | To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the proxy statement. | SECTION 14A SAY-ON-PAY VOTES |
- | - | 1858864.000000 | 0 | FOR |
1858864.000000 |
FOR |
- | - | |
| Mirum Pharmaceuticals, Inc. | 604749101 | US6047491013 | - | 06/05/2024 | To indicate, on an advisory basis, the preferred frequency of stockholder advisory votes on the compensation of the Company's named executive officers. | SECTION 14A SAY-ON-PAY VOTES |
- | - | 1858864.000000 | 0 | ONE YEAR |
1858864.000000 |
FOR |
- | - | |
| Neurocrine Biosciences, Inc. | 64125C109 | US64125C1099 | - | 05/22/2024 | Advisory vote on the compensation paid to the Company's named executive officers; | SECTION 14A SAY-ON-PAY VOTES |
- | - | 1055000.000000 | 0 | FOR |
1055000.000000 |
FOR |
- | - | |
| Nevro Corp. | 64157F103 | US64157F1030 | - | 05/23/2024 | To approve, on a non-binding, advisory basis, the compensation of the named executive officers as disclosed in the Company's proxy statement in accordance with the compensation disclosure rules of the Securities and Exchange Commission | SECTION 14A SAY-ON-PAY VOTES |
- | - | 1062943.000000 | 0 | FOR |
1062943.000000 |
FOR |
- | - | |
| Novavax, Inc. | 670002401 | US6700024010 | - | 07/11/2023 | The approval, on an advisory basis, of the compensation paid to our Named Executive Officers. | SECTION 14A SAY-ON-PAY VOTES |
- | - | 67107.000000 | 0 | FOR |
67107.000000 |
FOR |
- | - | |
| Novavax, Inc. | 670002401 | US6700024010 | - | 07/11/2023 | The approval, on an advisory basis, of holding future executive compensation advisory votes every three years, every two years, or every year. | SECTION 14A SAY-ON-PAY VOTES |
- | - | 67107.000000 | 0 | ONE YEAR |
67107.000000 |
FOR |
- | - | |
| Novavax, Inc. | 670002401 | US6700024010 | - | 06/13/2024 | The approval, on an advisory basis, of the compensation paid to our Named Executive Officers. | SECTION 14A SAY-ON-PAY VOTES |
- | - | 537625.000000 | 0 | FOR |
537625.000000 |
FOR |
- | - | |
| Nuvalent, Inc. | 670703107 | US6707031075 | - | 06/12/2024 | To approve, on an advisory basis, the compensation paid to our named executive officers. | SECTION 14A SAY-ON-PAY VOTES |
- | - | 217150.000000 | 0 | FOR |
217150.000000 |
FOR |
- | - | |
| Nuvalent, Inc. | 670703107 | US6707031075 | - | 06/12/2024 | To approve, on an advisory basis, the frequency of future advisory votes to approve the compensation paid to our named executive officers. | SECTION 14A SAY-ON-PAY VOTES |
- | - | 217150.000000 | 0 | ONE YEAR |
217150.000000 |
FOR |
- | - | |
| Oscar Health, Inc. | 687793109 | US6877931096 | - | 06/06/2024 | Approval, on an advisory (non-binding) basis, of the compensation of our named executive officers. | SECTION 14A SAY-ON-PAY VOTES |
- | - | 2110000.000000 | 0 | FOR |
2110000.000000 |
FOR |
- | - | |
| Pacira Biosciences, Inc. | 695127100 | US6951271005 | - | 06/11/2024 | Approval, on an advisory basis, of the compensation of our named executive officers. | SECTION 14A SAY-ON-PAY VOTES |
- | - | 976276.000000 | 0 | FOR |
976276.000000 |
FOR |
- | - | |
| Paratek Pharmaceuticals, Inc. | 699374302 | US6993743029 | - | 07/06/2023 | To consider an advisory vote on the compensation of our named executive officers. | SECTION 14A SAY-ON-PAY VOTES |
- | - | 1675251.000000 | 0 | FOR |
1675251.000000 |
FOR |
- | - | |
| Paratek Pharmaceuticals, Inc. | 699374302 | US6993743029 | - | 07/06/2023 | To consider an advisory vote on the frequency of holding future advisory votes on the compensation of our named executive officers. | SECTION 14A SAY-ON-PAY VOTES |
- | - | 1675251.000000 | 0 | ONE YEAR |
1675251.000000 |
FOR |
- | - | |
| Paratek Pharmaceuticals, Inc. | 699374302 | US6993743029 | - | 09/18/2023 | To approve, by a non-binding, advisory vote, certain compensation arrangements for the Company's named executive officers in connection with the Merger. | SECTION 14A SAY-ON-PAY VOTES |
- | - | 1734036.000000 | 0 | FOR |
1734036.000000 |
FOR |
- | - | |
| Penumbra, Inc. | 70975L107 | US70975L1070 | - | 06/05/2024 | To approve, on an advisory basis, the compensation of Penumbra, Inc.'s named executive officers as disclosed in the proxy statement. | SECTION 14A SAY-ON-PAY VOTES |
- | - | 428.000000 | 0 | FOR |
428.000000 |
FOR |
- | - | |
| Phreesia, Inc. | 71944F106 | US71944F1066 | - | 06/26/2024 | To approve, on a non-binding, advisory basis, the compensation of our named executive officers, as disclosed in the Proxy Statement. | SECTION 14A SAY-ON-PAY VOTES |
- | - | 1892034.000000 | 0 | FOR |
1892034.000000 |
FOR |
- | - | |
| Pliant Therapeutics, Inc. | 729139105 | US7291391057 | - | 06/13/2024 | To approve, by non-binding advisory vote, the resolution approving named executive officer compensation. | SECTION 14A SAY-ON-PAY VOTES |
- | - | 420.000000 | 0 | AGAINST |
420.000000 |
AGAINST |
- | - | |
| Prothena Corporation plc | G72800108 | IE00B91XRN20 | - | 05/14/2024 | To approve, in a non-binding advisory vote, the compensation of the executive officers named in the Company's Proxy Statement for the Annual General Meeting. | SECTION 14A SAY-ON-PAY VOTES |
- | - | 224932.000000 | 0 | FOR |
224932.000000 |
FOR |
- | - | |
| Pulmonx Corporation | 745848101 | US7458481014 | - | 05/16/2024 | To conduct a non-binding advisory vote to approve our executive compensation. | SECTION 14A SAY-ON-PAY VOTES |
- | - | 652400.000000 | 0 | AGAINST |
652400.000000 |
AGAINST |
- | - | |
| Revolution Medicines, Inc. | 76155X100 | US76155X1000 | - | 06/20/2024 | To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement pursuant to the compensation disclosure rules of the Securities and Exchange Commission ("Say-on-Pay"). | SECTION 14A SAY-ON-PAY VOTES |
- | - | 826905.000000 | 0 | FOR |
826905.000000 |
FOR |
- | - | |
| Sarepta Therapeutics, Inc. | 803607100 | US8036071004 | - | 06/06/2024 | advisory vote to approve, on a non-binding basis, name executive officer compensation | SECTION 14A SAY-ON-PAY VOTES |
- | - | 327600.000000 | 0 | FOR |
327600.000000 |
FOR |
- | - | |
| Shockwave Medical, Inc. | 82489T104 | US82489T1043 | - | 05/29/2024 | To approve, on a non-binding advisory basis, the compensation that may be paid or become payable to Shockwave's named executive officers that is based on or otherwise relates to the Merger. | SECTION 14A SAY-ON-PAY VOTES |
- | - | 71582.000000 | 0 | AGAINST |
71582.000000 |
AGAINST |
- | - | |
| Spero Therapeutics, Inc. | 84833T103 | US84833T1034 | - | 10/05/2023 | To approve by an advisory vote the compensation of the Company's named executive officers, as disclosed in the proxy statement. | SECTION 14A SAY-ON-PAY VOTES |
- | - | 500412.000000 | 0 | FOR |
500412.000000 |
FOR |
- | - | |
| Spero Therapeutics, Inc. | 84833T103 | US84833T1034 | - | 10/05/2023 | To approve by an advisory vote the frequency of holding an advisory vote on compensation of the Company's named executive officers. | SECTION 14A SAY-ON-PAY VOTES |
- | - | 500412.000000 | 0 | ONE YEAR |
500412.000000 |
FOR |
- | - | |
| Surgery Partners, Inc. | 86881A100 | US86881A1007 | - | 06/06/2024 | Approval, on an advisory basis, of the compensation paid by the Company to its named executive officers. | SECTION 14A SAY-ON-PAY VOTES |
- | - | 4664.000000 | 0 | FOR |
4664.000000 |
FOR |
- | - | |
| Talphera, Inc. | 00444T209 | US00444T2096 | - | 06/24/2024 | To approve, on an advisory basis, the compensation of our named executive officers. | SECTION 14A SAY-ON-PAY VOTES |
- | - | 313690.000000 | 0 | FOR |
313690.000000 |
FOR |
- | - | |
| Travere Therapeutics, Inc. | 89422G107 | US89422G1076 | - | 05/08/2024 | To approve, on an advisory basis, the compensation of the Company's named executive officers. | SECTION 14A SAY-ON-PAY VOTES |
- | - | 3373154.000000 | 0 | FOR |
3373154.000000 |
FOR |
- | - | |
| Ultragenyx Pharmaceutical Inc. | 90400D108 | US90400D1081 | - | 06/18/2024 | Advisory (non-binding) vote to approve the compensation of our named executive officers. | SECTION 14A SAY-ON-PAY VOTES |
- | - | 1756055.000000 | 0 | FOR |
1756055.000000 |
FOR |
- | - | |
| UnitedHealth Group Incorporated | 91324P102 | US91324P1021 | - | 06/03/2024 | Advisory approval of the Company's executive compensation. | SECTION 14A SAY-ON-PAY VOTES |
- | - | 230000.000000 | 0 | FOR |
230000.000000 |
FOR |
- | - | |
| Viking Therapeutics, Inc. | 92686J106 | US92686J1060 | - | 05/21/2024 | TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS. | SECTION 14A SAY-ON-PAY VOTES |
- | - | 3460.000000 | 0 | FOR |
3460.000000 |
FOR |
- | - | |
| Warby Parker Inc. | 93403J106 | US93403J1060 | - | 06/07/2024 | Approval, on an advisory (non-binding) basis, of the compensation of the Company's named executive officers. | SECTION 14A SAY-ON-PAY VOTES |
- | - | 35970.000000 | 0 | FOR |
35970.000000 |
FOR |
- | - | |
| West Pharmaceutical Services, Inc. | 955306105 | US9553061055 | - | 04/23/2024 | Advisory vote to approve named executive officer compensation; | SECTION 14A SAY-ON-PAY VOTES |
- | - | 103254.000000 | 0 | FOR |
103254.000000 |
FOR |
- | - | |
| Xenon Pharmaceuticals Inc. | 98420N105 | CA98420N1050 | - | 06/04/2024 | Compensation of Named Executive Officers Approve, on an advisory basis, the compensation of the Corporation's named executive officers | SECTION 14A SAY-ON-PAY VOTES |
- | - | 1255577.000000 | 0 | FOR |
1255577.000000 |
FOR |
- | - | |
| Zai Lab Limited | G9887T116 | KYG9887T1168 | - | 06/18/2024 | THAT, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the proxy statement, is hereby approved. | SECTION 14A SAY-ON-PAY VOTES |
- | - | 1900000.000000 | 0 | AGAINST |
1900000.000000 |
AGAINST |
- | - | |
| Zai Lab Limited | 98887Q104 | US98887Q1040 | - | 06/18/2024 | THAT, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the proxy statement, is hereby approved. | SECTION 14A SAY-ON-PAY VOTES |
- | - | 284556.000000 | 0 | AGAINST |
284556.000000 |
AGAINST |
- | - | |
[Repeat as Necessary]